Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed …

JH Sampson, AB Heimberger, GE Archer… - Journal of clinical …, 2010 - ascopubs.org
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

[引用][C] Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH SAMPSON, AB HEIMBERGER… - Journal of clinical …, 2010 - pascal-francis.inist.fr
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor
Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma …

[PDF][PDF] Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH Sampson, AB Heimberger, GE Archer… - J Clin …, 2010 - researchgate.net
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

[HTML][HTML] Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH Sampson, AB Heimberger, GE Archer… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

[PDF][PDF] Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH Sampson, AB Heimberger, GE Archer, KD Aldape… - J Clin Oncol, 2010 - academia.edu
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed …

JH Sampson, AB Heimberger… - Journal of clinical …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH Sampson, AB Heimberger, GE Archer… - Journal of Clinical …, 2010 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Immunologic targeting of tumor-
specific gene mutations may allow precise eradication of neoplastic cells without toxicity …

[PDF][PDF] Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly …

JH Sampson, AB Heimberger, GE Archer… - J Clin …, 2010 - scholar.archive.org
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed …

JH Sampson, AB Heimberger, GE Archer… - Journal of Clinical …, 2010 - europepmc.org
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed …

JH Sampson, AB Heimberger… - Journal of Clinical …, 2010 - scholars.northwestern.edu
Purpose: Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …